See the DrugPatentWatch profile for Amlodipine
What market share does amlodipine besylate have?
Market share figures for “amlodipine besylate” specifically are rarely published as a standalone number because most industry reporting is done for the broader drug/brand category (such as amlodipine) rather than a specific salt (besylate). That means the most commonly tracked market share data is usually reported for:
- Amlodipine (overall)
- Specific brands (most notably Norvasc in the US)
- The therapeutic class (calcium-channel blockers) rather than the besylate salt alone
If you tell me the country/region and the reporting basis you want (prescription volume vs. dollars, and brand vs. total), I can help narrow to the closest available “market share” definition.
How is amlodipine market share usually measured (brand vs. generic, units vs. dollars)?
Pharmaceutical market share is typically split into different views:
- Brand market share vs. total market share (brand + generic)
- By sales value (revenue dollars) or by volume (prescriptions/tablets)
- By geography (US, EU5, UK, etc.)
- By formulation class (oral tablets, vs. extended-release, etc.—sometimes even split by strength)
For amlodipine, the “besylate” form is the common salt used in many products, but generic competition usually means overall market share is concentrated across multiple generic manufacturers rather than one “amlodipine besylate” producer.
Is there a difference between “amlodipine” and “amlodipine besylate” in market share reports?
In most market-share datasets, “amlodipine besylate” is not treated as its own separate market; it is one way the active ingredient is presented. Many reports group all amlodipine salts together under “amlodipine” to reflect therapeutic equivalence and interchangeability.
Which company holds the largest share for amlodipine in practice?
In the US, the leading single brand has historically been Norvasc (amlodipine). However, after generic entry, the largest combined share is typically held by generics overall (across many manufacturers), even if one brand remains a top single SKU.
Can you share the location and time period you mean?
Market share depends heavily on:
- Market (US vs. other countries)
- Year/quarter
- Metric (value vs. prescriptions)
- Whether you want brand-only, generic-only, or total (brand + generic)
Reply with something like “US, 2023, prescription volume” (or “US, sales dollars, Norvasc share”), and I’ll target the most relevant market-share view.